drugset / Trial / NCT06331520
NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens
RandomizedParallel-groupOpen-labelPrevention
Summary
The objective of this Prospective, randomized, non inferiority phase III trial is to confirm the efficacy and saftey of dexamethasone-sparing combined with netupitant/palonostron and olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2025-08-01
- Completion
- 2025-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexamethasone | Small molecule | 6 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 8 mg | Oral |
| Background | Netupitant | Small molecule | — | Oral |
| Background | Olanzapine | Small molecule | 5 mg | Oral |
| Background | Palonosetron | Other / unclassified | — | Oral |